Correvio Pharma (CORV)

[surf1944]

8:46AM Cardiome Pharma announces publication of positive data from an observational, retrospective study of BRINAVESS (CRME) 4.10 : Co announced publication of positive data from an observational, retrospective study performed at the Skane University Hospital in Malmo, Sweden. The study included 251 recent-onset atrial fibrillation patients who received 355 BRINAVESS treatments during the period between Jan 15, 2011 and April 15, 2013. During the observation period, 70% of the AF patients treated with BRINAVESS converted with a median time of 11 minutes. Conversion efficacy was 76% in patients with AF duration <10 hours. The median time spent in the ER for patients who converted on BRINAVESS was 6.5 hours. These results are published in the Oct 2013 issue of The European Journal of Cardiovascular Medicine.